{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-098928","form_type":"8-K/A","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2023-12-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.403825+00:00","generated_at":"2026-06-07T06:58:07.208108+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Onconetix issues $75M in stock for Proteomedix; prior holders diluted to 5.4%","bullets":["Onconetix issued 3,675,414 common shares (19.9% of outstanding) and 2,696,729 Series B convertible shares (convertible into 269,672,900 common) for Proteomedix.","Aggregate consideration valued at ~$75M; Tungsten Advisors received $7.5M in Exchange Shares as compensation.","Post-closing common outstanding: 22,061,746; after conversion, pre-closing stockholders will own ~5.4%.","Lock-up of 6 months after stockholder approval; Series B converts automatically or cash settles by Jan 1, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-098928","json":"https://secwatch.observer/filing/0001213900-23-098928.json","markdown":"https://secwatch.observer/filing/0001213900-23-098928.md","text":"https://secwatch.observer/filing/0001213900-23-098928.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023098928/0001213900-23-098928-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023098928/ea190756-8ka1_onconetix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T06:58:07.208108+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"106c9b74b91720bf3b67be7b6bad0504f6362298","claim":"Onconetix, Inc. entered into Share Exchange Agreement with Proteomedix AG valued at Aggregate value of Exchange Shares at Closing approximately $75,000,000; Onconetix issued 3,675,414 (effective 2023-12-15).","evidence_excerpt":"On December 15, 2023, Onconetix, Inc, a Delaware corporation f/k/a Blue Water Biotech, Inc. (“ Onconetix ” or the “ Buyer ”), entered into a Share Exchange Agreement","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023098928/0001213900-23-098928-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Proteomedix AG"},{"label":"Value","value":"Aggregate value of Exchange Shares at Closing approximately $75,000,000; Onconetix issued 3,675,414"},{"label":"Effective","value":"2023-12-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}